Ocular Therapeutix, Inc. 0OT.F Stock
Ocular Therapeutix, Inc. Price Chart
Ocular Therapeutix, Inc. 0OT.F Financial and Trading Overview
Ocular Therapeutix, Inc. stock price | 5.55 EUR |
Previous Close | 4.71 EUR |
Open | 4.45 EUR |
Bid | 4.5 EUR x 140000 |
Ask | 4.63 EUR x 140000 |
Day's Range | 4.45 - 4.45 EUR |
52 Week Range | 2.41 - 7.3 EUR |
Volume | 750 EUR |
Avg. Volume | 707 EUR |
Market Cap | 345.3M EUR |
Beta (5Y Monthly) | 1.298943 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.03 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 23.43 EUR |
0OT.F Valuation Measures
Enterprise Value | 391.43M EUR |
Trailing P/E | N/A |
Forward P/E | -6.4550724 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 6.6812763 |
Price/Book (mrq) | 35.632 |
Enterprise Value/Revenue | 7.574 |
Enterprise Value/EBITDA | -4.813 |
Trading Information
Ocular Therapeutix, Inc. Stock Price History
Beta (5Y Monthly) | 1.298943 |
52-Week Change | 52.28% |
S&P500 52-Week Change | 20.43% |
52 Week High | 7.3 EUR |
52 Week Low | 2.41 EUR |
50-Day Moving Average | 5.57 EUR |
200-Day Moving Average | 4.46 EUR |
0OT.F Share Statistics
Avg. Volume (3 month) | 707 EUR |
Avg. Daily Volume (10-Days) | 561 EUR |
Shares Outstanding | 77.52M |
Float | 68.58M |
Short Ratio | N/A |
% Held by Insiders | 1.14% |
% Held by Institutions | 52.09% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -171.84% |
Operating Margin (ttm) | -161.31% |
Gross Margin | -15.25% |
EBITDA Margin | -157.37% |
Management Effectiveness
Return on Assets (ttm) | -32.95% |
Return on Equity (ttm) | -198.45% |
Income Statement
Revenue (ttm) | 51.68M EUR |
Revenue Per Share (ttm) | 0.67 EUR |
Quarterly Revenue Growth (yoy) | 1.40% |
Gross Profit (ttm) | -6508000 EUR |
EBITDA | -81335000 EUR |
Net Income Avi to Common (ttm) | -88814000 EUR |
Diluted EPS (ttm) | -1.07 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 79.03M EUR |
Total Cash Per Share (mrq) | 1.02 EUR |
Total Debt (mrq) | 64.61M EUR |
Total Debt/Equity (mrq) | 665.34 EUR |
Current Ratio (mrq) | 3.606 |
Book Value Per Share (mrq) | 0.125 |
Cash Flow Statement
Operating Cash Flow (ttm) | -60976000 EUR |
Levered Free Cash Flow (ttm) | -37272124 EUR |
Profile of Ocular Therapeutix, Inc.
Country | Germany |
State | MA |
City | Bedford |
Address | 24 Crosby Drive |
ZIP | 01730 |
Phone | 781 357 4000 |
Website | https://www.ocutx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 274 |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Q&A For Ocular Therapeutix, Inc. Stock
What is a current 0OT.F stock price?
Ocular Therapeutix, Inc. 0OT.F stock price today per share is 5.55 EUR.
How to purchase Ocular Therapeutix, Inc. stock?
You can buy 0OT.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ocular Therapeutix, Inc.?
The stock symbol or ticker of Ocular Therapeutix, Inc. is 0OT.F.
Which industry does the Ocular Therapeutix, Inc. company belong to?
The Ocular Therapeutix, Inc. industry is Biotechnology.
How many shares does Ocular Therapeutix, Inc. have in circulation?
The max supply of Ocular Therapeutix, Inc. shares is 154.89M.
What is Ocular Therapeutix, Inc. Price to Earnings Ratio (PE Ratio)?
Ocular Therapeutix, Inc. PE Ratio is now.
What was Ocular Therapeutix, Inc. earnings per share over the trailing 12 months (TTM)?
Ocular Therapeutix, Inc. EPS is -1.03 EUR over the trailing 12 months.
Which sector does the Ocular Therapeutix, Inc. company belong to?
The Ocular Therapeutix, Inc. sector is Healthcare.